Krystexxa Clinical Trial for Uncontrolled Gout

Uncontrolled gout — also known as recurrent or refractory gout — is a chronic condition that affects the joints due to a buildup of uric acid and persists despite taking gout medication. Left untreated, gout can cause nodules called tophi to develop around the joints. Patients with uncontrolled gout are also at a higher risk of developing diabetes as well as chronic kidney disease and heart disease.

In this trial we will study the potential for Krystexxa in combination with methotrexate to increase the response rate seen with Krystexxa alone.

Who can take part in the study?

We are conducting this Krystexxa MIRROR study for adults diagnosed with uncontrolled gout. The study will be a randomized, double-blind, placebo-controlled study to test the safety and efficacy of the treatment.



18 years or older

Key Inclusion and Exclusion Criteria:

Patients must have a diagnosis of uncontrolled gout as defined by elevated uric acid levels despite medication therapy and symptoms of gout, including at least one of the following:

  • Presence of at least one tophus
  • Two or more flares in the past 12 months
  • Presence of gouty arthritis

Patient Commitment Duration:

Approximately 86 weeks



All the staff were competent and very kind. I am sure I worked with at least 10 different staff members and each one talked with me and treated me like a friend. I commend this business on their positive work environment and the attitude their staff exhibits.



Steve Beur


Interested in Other Enrolling Clinical Trials?

All of our studies are approved by the Food and Drug Administration (FDA). To find out more, click on the links below.